指南与共识肿瘤 PET/CT核素与放射性配体治疗

经PSMA PET/CT共识声明与RECIP 1.0评估的177Lu-PSMA放射性配体治疗后PSMA PET肿瘤体积的预后价值

Prognostic Value of Tumor Volume Assessment on PSMA PET After 177Lu-PSMA Radioligand Therapy Evaluated by PSMA PET/CT Consensus Statement and RECIP 1.0.
指南 / 共识 · J Nucl Med · 2022-10-27

本回顾性研究纳入70例接受177Lu-PSMA放射性配体治疗的转移性去势抵抗性前列腺癌患者,分别用68Ga-PSMA-11或18F-PSMA-1007 PET/CT评估基线PSMATV50及其随访变化比值ΔPSMATV50。两种示踪剂下基线PSMATV50较高及ΔPSMATV50较高均与较短总生存期相关,将ΔPSMATV50整合入PSMA PET/CT共识声明与RECIP 1.0后两分类系统均具较高预后判别力。

要点

  • PSMATV50测定在所有检查中技术上可行,基于病灶SUVmax 50%阈值的半自动方法适用。
  • 68Ga-PSMA-11组基线PSMATV50较高与较短OS相关(HR 1.29,95%CI 1.05-1.55,P=0.009)。
  • 将ΔPSMATV50整合入PSMA PET/CT共识声明与RECIP 1.0后,两系统对OS判别力均较高。

核心结论

  • PSMATV50与ΔPSMATV50对68Ga-PSMA-11及18F-PSMA-1007 PET/CT扫描均能预测总生存期。
  • 将ΔPSMATV50整合入PSMA PET/CT共识声明和RECIP 1.0后,两种分类系统均提供同等高的预后价值。

研究设计与样本

  • 本回顾性研究纳入70例接受PSMA放射性配体治疗的转移性去势抵抗性前列腺癌患者。
  • 33例患者用68Ga-PSMA-11 PET/CT监测,37例患者用18F-PSMA-1007 PET/CT监测。
  • 基线与PSMA放射性配体治疗2-4周期后随访的PET/CT扫描由2名读者分别分析。
  • 采用Cox比例风险回归分析基线PSMATV50及随访时ΔPSMATV50(以比值表示)与OS的相关性。
  • 采用Gönen和Heller一致性概率估计评估各分类系统的判别力。

主要发现

  • PSMATV50测定在所有检查中技术上可行。
  • 68Ga-PSMA-11组基线PSMATV50较高与较短OS相关(HR 1.29,95%CI 1.05-1.55,P=0.009)。
  • 68Ga-PSMA-11组ΔPSMATV50较高与较短OS相关(HR 1.83,95%CI 1.08-3.09,P=0.024)。
  • 18F-PSMA-1007组基线PSMATV50较高与较短OS相关(HR 1.84,95%CI 1.13-2.99,P=0.014)。
  • 18F-PSMA-1007组ΔPSMATV50较高与较短OS相关(HR 1.23,95%CI 1.04-1.51,P=0.03)。

关键数值与推荐

  • PSMA PET/CT共识声明对OS的判别一致性概率估计为0.73。
  • RECIP 1.0对OS的判别一致性概率估计为0.74。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Quantitative evaluation of prostate-specific membrane antigen (PSMA)-targeting PET/CT remains challenging but is urgently needed for the use of standardized PET-based response criteria, such as the PSMA PET/CT consensus statement or Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0). A recent study evaluated the prognostic value of whole-body tumor volume using a semiautomatic method relying on a 50% threshold of lesion SUVmax (PSMATV50). In the present study, we analyzed the suitability of this approach comparing 18F-PSMA-1007 with 68Ga-PSMA-11 PET/CT scans and the potential of PSMATV50 for the prediction of overall survival (OS) in patients before 177Lu-PSMA radioligand therapy (RLT). Moreover, PSMATV50 was integrated into the PSMA PET/CT consensus statement as well as RECIP 1.0, and the prognostic value of these response classification systems was compared. Methods: This retrospective study included 70 patients with metastatic castration-resistant prostate cancer undergoing PSMA RLT. Thirty-three patients were monitored by 68Ga-PSMA-11 PET/CT, and 37 patients by 18F-PSMA-1007 PET/CT. PET/CT scans before (baseline) and at the end of PSMA RLT after 2-4 cycles (follow-up) were separately analyzed by 2 readers. PSMATV50 at baseline and its change at the time of follow-up (ΔPSMATV50, expressed as a ratio) were correlated with OS using Cox proportional-hazards regression. The results of both subgroups were compared. The integration of ΔPSMATV50 in existing response classification systems was evaluated. To assess and compare the discriminatory strength of these classification systems, Gönen and Heller concordance probability estimates were calculated. Results: PSMATV50 determination was technically feasible in all examinations. A higher PSMATV50 at baseline and a higher ΔPSMATV50 were strongly associated with a shorter OS for both 68Ga-PSMA-11 (PSMATV50: hazard ratio [HR] of 1.29 [95% CI, 1.05-1.55], P = 0.009; ΔPSMATV50: HR of 1.83 [95% CI, 1.08-3.09], P = 0.024) and 18F-PSMA-1007 (PSMATV50: HR of 1.84 [95% CI, 1.13-2.99], P = 0.014; ΔPSMATV50: HR of 1.23 [95% CI, 1.04-1.51], P = 0.03). Response assessment provided high discriminatory power for OS for the PSMA PET/CT consensus statement (concordance probability estimate, 0.73) as well as RECIP 1.0 (concordance probability estimate, 0.74). Conclusion: PSMATV50 and ΔPSMATV50 proved to be predictive of OS not only for 68Ga-PSMA-11 but also for 18F-PSMA-1007 PET/CT scans. Subsequent integration of ΔPSMATV50 into the PSMA PET/CT consensus statement and RECIP 1.0 provided equally high prognostic value for both classification systems.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Kind F, Eder AC, Jilg CA, et al. Prognostic Value of Tumor Volume Assessment on PSMA PET After 177Lu-PSMA Radioligand Therapy Evaluated by PSMA PET/CT Consensus Statement and RECIP 1.0. J Nucl Med. 2022. PMID: 36302658. doi:10.2967/jnumed.122.264489

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。